Project Type(s):
Clinical Research
Principal Investigator(s):
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer’s disease.
Project Period:
April 4, 2022
Funding Type(s):
Private company/industry
Funder(s):
Biogen
Biogen
Geographic Area(s):
Alaska, King County, Seattle/Puget Sound, University of Washington, Washington
Practice Type(s):
Outpatient
Patient Population(s):
Adults
Targeted Condition(s):
Cognitive Disorders
